prikaz prve stranice dokumenta Successful treatment of genotype 3 hepatitis C infection in a noncirrhotic HIV infected patient on chronic dialysis with the combination of sofosbuvir and velpatasvir
  Download
PDF 168.77 KB
Scientific paper - Case study
Successful treatment of genotype 3 hepatitis C infection in a noncirrhotic HIV infected patient on chronic dialysis with the combination of sofosbuvir and velpatasvir
Medicine, 97 (2018), 51; e13671. https://doi.org/10.1097/MD.0000000000013671
Begovac, Josip; Krznarić, Juraj; Bogdanić, Nikolina; Močibob, Loris; Zekan, Šime

Institutional repository: Dr Med - University of Zagreb School of Medicine Digital Repository

Cite this document

Begovac, J., Krznarić, J., Bogdanić, N., Močibob, L. & Zekan, Š. (2018). Successful treatment of genotype 3 hepatitis C infection in a noncirrhotic HIV infected patient on chronic dialysis with the combination of sofosbuvir and velpatasvir. Medicine, 97. (51). doi: 10.1097/MD.0000000000013671

Begovac, Josip, et al. "Successful treatment of genotype 3 hepatitis C infection in a noncirrhotic HIV infected patient on chronic dialysis with the combination of sofosbuvir and velpatasvir." Medicine, vol. 97, no. 51, 2018. https://doi.org/10.1097/MD.0000000000013671

Begovac, Josip, Juraj Krznarić, Nikolina Bogdanić, Loris Močibob and Šime Zekan. "Successful treatment of genotype 3 hepatitis C infection in a noncirrhotic HIV infected patient on chronic dialysis with the combination of sofosbuvir and velpatasvir." Medicine 97, no. 51 (2018). https://doi.org/10.1097/MD.0000000000013671

Begovac, J., et al. (2018) 'Successful treatment of genotype 3 hepatitis C infection in a noncirrhotic HIV infected patient on chronic dialysis with the combination of sofosbuvir and velpatasvir', Medicine, 97(51). doi: 10.1097/MD.0000000000013671

Begovac J, Krznarić J, Bogdanić N, Močibob L, Zekan Š. Successful treatment of genotype 3 hepatitis C infection in a noncirrhotic HIV infected patient on chronic dialysis with the combination of sofosbuvir and velpatasvir. Medicine [Internet]. 2018 December [cited 2024 July 13];97(51). doi: 10.1097/MD.0000000000013671

J. Begovac, J. Krznarić, N. Bogdanić, L. Močibob and Š. Zekan, "Successful treatment of genotype 3 hepatitis C infection in a noncirrhotic HIV infected patient on chronic dialysis with the combination of sofosbuvir and velpatasvir", Medicine, vol. 97, no. 51, December 2018. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:507305. [Accessed: 13 July 2024]

Metadata
Title (english)Successful treatment of genotype 3 hepatitis C infection in a noncirrhotic HIV infected patient on chronic dialysis with the combination of sofosbuvir and velpatasvir
AuthorJosip Begovac
AuthorJuraj Krznarić
AuthorNikolina Bogdanić
AuthorLoris Močibob
AuthorŠime Zekan
Author's institutionUniversity of Zagreb
School of Medicine
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Abstract (english)
RATIONALE: Data on anti-HCV therapy in patients on dialysis is still evolving. Sofosbuvir is mainly eliminated through the renal route and there is controversy about its use in these patients. ----- PATIENT CONCERNS: We describe a 53-year-old male patient with HCV genotype 3 and human immunodeficiency type 1 (HIV) infection on chronic dialysis. HIV infection was diagnosed in 1987 and since July 2007 the patient was compliant with his antiretroviral therapy (ART) and had an undetectable plasma HIV viral load on all follow-up measurements. The patient was known to have HCV infection since 1997 but has never been treated for chronic hepatitis C. Because of progressive renal impairment dialysis started in 2005. ----- DIAGNOSIS: Before anti-HCV treatment commenced the patient liver transient elastography (FibroScan) indicated F3 fibrosis (stiffness, 11.6 kPa) and his HCV RNA viral load was 320,798 IU/mL (Abbott RealTime HCV assay). ----- INTERVENTION: Fixed dose combination of sofosbuvir/velpatasvir (400 mg/100 mg) for 11 weeks. ----- OUTCOMES: Twelve weeks after treatment cessation HCV RNA was undetectable, hence the patient achieved a sustained virologic response. The drugs were well tolerated and the patient did not report any side effects. ----- LESSONS: Sofosbuvir/velpatasvir may be an option for HCV genotype 3 infection in patients coinfected with HIV on long-term dialysis.
Keywords (english)
Languageenglish
Publication typeScientific paper - Case study
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleMedicine
Numberingvol. 97, no. 51, e13671
p-ISSN0025-7974
DOIhttps://doi.org/10.1097/MD.0000000000013671
URN:NBNurn:nbn:hr:105:507305
Publication2018-12
Document URLhttps://doi.org/10.1097/MD.0000000000013671
Type of resourceText
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2024-03-28 09:59:44